Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
256.8 USD | +1.61% | -2.28% | +11.01% |
May. 29 | Agilent lowers full-year revenue forecast on slowing demand from its biotech clients | RE |
May. 23 | Some of the biggest splits in Corporate America | RE |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 43.39 and 35.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.01% | 190B | B- | ||
+7.01% | 217B | B | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.48% | 64.59B | A- | ||
+13.95% | 52.36B | B+ | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.6B | - | ||
+19.95% | 30.31B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DHR Stock
- Ratings Danaher Corporation